Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret

@article{Robichaud1999EmesisIB,
  title={Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret},
  author={Annette Robichaud and F. David Tattersall and I Choudhury and Ian W. Rodger},
  journal={Neuropharmacology},
  year={1999},
  volume={38},
  pages={289-297}
}
Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) has been investigated in the ferret. The PDE IV inhibitors studied were: RS14203, R-rolipram and CT-2450 (i.e. (R)-N-[4-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethyl]phenyl ]N'-ethylurea), in addition to the less active enantiomers S-rolipram and CT-3405. Following oral administrations, different emetic profiles were observed with time. Emesis induced by RS14203 exhibited a dose-response relationship… Expand
Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.
TLDR
Findings strongly support the hypothesis that inhibition of PDE4D is pivotal to the anesthesia-reversing effect of PMNPQ and is likely responsible for emesis induced by PDE 4 inhibitors. Expand
PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
TLDR
The studies suggest that the ferret is an appropriate model to study emesis induced by PDE4 inhibitors and that these compounds trigger the emetic reflex via a noradrenergic pathway, mimicking the pharmacological actions of a pre-synaptic alpha(2)-adrenoceptor inhibition. Expand
Assessing the emetic potential of PDE4 inhibitors in rats
TLDR
This model is functionally coupled to PDE4, specific to alpha2‐adrenoceptors and relevant to Pde4 inhibitor‐induced emesis and provides a novel way of evaluating the emetic potential of PDE 4 inhibitors in rats. Expand
ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.
TLDR
Although ASP3258 inhibited airway inflammation completely, it had no emetic activity, and may be useful in treating airway inflammatory diseases such as asthma and COPD. Expand
Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain.
TLDR
It is concluded that the emetic effect of phosphodiesterase 4 inhibitors is caused at least in part via binding to the high-affinity rolipram binding site in brain in vivo. Expand
Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumin-induced asthma murine model.
TLDR
In vivo study using ovalbumin-induced asthmatic mice revealed that PDE-423 reduced methacholine-stimulated airway hyperreactivity in a dose-dependent manner by once daily oral administration, in parallel with decreased eosinophil peroxidase activity and improved lung histology. Expand
CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration—In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window
TLDR
CHF6001 was found effective and extremely well tolerated upon topical administration in relevant animal models, and may represent a step forward in PDE4 inhibition for the treatment of asthma and chronic obstructive respiratory disease. Expand
Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors.
TLDR
The synthesis and the biological evaluation of new potent phosphodiesterase type 4 (PDE4) inhibitors are presented and the identification of (-)-3n which exhibited a good PDE4 inhibitor activity and an improved pharmacokinetic profile over L-791,943 is presented. Expand
Differential effects of PDE4 inhibitors on cortical neurons and T-lymphocytes.
TLDR
The findings indicate that the high affinity PDE4 conformer exists at a high level in cortical neurons and is important in the regulation of cAMP. Expand
The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
TLDR
In contrast to YM976, YM-393059 did not shorten the duration of alpha2-adrenoceptor agonist-induced sleep in mice, which is a model for the assessment of the typical side effects caused by PDE4 inhibitors, nausea and emesis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
TLDR
A novel series of 4-(3-alkoxy-4-methoxyphenyl)benzoic acids and their corresponding carboxamides were prepared and evaluated for their PDE-IV inhibitory and rolipram binding site properties and 4-phenylbutoxy and phenylpentoxy analogues provided the desired activity profile. Expand
Anti‐inflammatory activity of phosphodiesterase (PDE)‐IV inhibitors in acute and chronic models of inflammation
TLDR
A potential therapeutic use for PDE‐IV‐specific inhibitors in inflammatory disease such as rheumatoid arthritis, septic shock and other inflammatory diseases where TNF‐α has been postulated to be a contributing factor in the pathology of the disease is suggested. Expand
Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets
TLDR
It is shown that brain penetration is essential for the anti-emetic action of systemically administered NK1 receptor antagonists with and without brain penetration to central NK1 receptors sites. Expand
Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan‐stimulated respiratory burst by ‘type IV’‐selective PDE inhibitors
TLDR
It is concluded that eosinophil respiratory burst activity induced by OZ can be regulated by intracellular cyclic AMP and that the levels of cyclicAMP are controlled exclusively by a rolipram‐ and denbufylline‐sensitive PDE isoenzyme that resembles a type IV species. Expand
5‐HT3 receptor antagonists injected into the area postrema inhibit cisplatin‐induced emesis in the ferret
TLDR
Results confirm a role of 5‐HT, and in particular 5‐ HT3 receptors, in the control of cisplatin‐induced emesis, and show that at least one functional site for these receptors in modulating the emetic response is the area postrema, the locus of the chemoreceptor trigger zone. Expand
The anti‐emetic effects of CP‐99,994 in the ferret and the dog: role of the NK1 receptor
TLDR
The hypothesis that the NK1 receptor antagonist properties of CP‐99,994 are responsible for its broad spectrum anti‐emetic effects is supported and it is suggested that CP‐ 99,994 acts within the brainstem, most probably within the nucleus tractus solitarius although the involvement of the area postrema could not be excluded. Expand
Effects of theophylline and rolipram on antigen‐induced airway responses in neonatally immunized rabbits
TLDR
With the dosing regimes used, both rolipram and theophylline inhibited eosinophil recruitment, whilst only ro Lipram prevented the development of airway hyperresponsiveness, neither agent inhibited the acute bronchoconstriction due to inhaled antigen. Expand
The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret.
TLDR
The tachykinin NK1 receptor antagonist CP-99,994 and its inactive enantiomer CP-100,263 attenuated the retching and vomiting induced by cisplatin in the ferret. Expand
Enantioselective inhibition of ampomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994
These studies have examined the effects of the selective neurokinin1 (NK1) receptor antagonist CP-99,994 on the retching and vomiting response to apomorphine. CP-99,994 (1-3 mg/kg i.p.) attenuatedExpand
Serotonin and the Scientific Basis of Anti-Emetic Therapy,
TLDR
A concise history of the critical concepts and experiments of emesis research is presented, including evidence for the involvement of serotonin in acute cytotoxic-induced emesis andLimitations in the efficacy of 5-HT3 receptor antagonists are noted. Expand
...
1
2
3
...